초록 ▼

The present invention advances prior art intensive repair serums by providing an intensive repair serum formulated with Morinda citrifolia from the Indian Mulberry plant. The addition of Morinda citrifolia to the serum of the present invention serves to provide significant skin care advantages not f

The present invention advances prior art intensive repair serums by providing an intensive repair serum formulated with Morinda citrifolia from the Indian Mulberry plant. The addition of Morinda citrifolia to the serum of the present invention serves to provide significant skin care advantages not found in prior art intensive repair serums.

대표청구항 ▼

The present invention advances prior art intensive repair serums by providing an intensive repair serum formulated with Morinda citrifolia from the Indian Mulberry plant. The addition of Morinda citrifolia to the serum of the present invention serves to provide significant skin care advantages not f

The present invention advances prior art intensive repair serums by providing an intensive repair serum formulated with Morinda citrifolia from the Indian Mulberry plant. The addition of Morinda citrifolia to the serum of the present invention serves to provide significant skin care advantages not found in prior art intensive repair serums. optionally substituted with one to three substituents selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; wherein said alkyl groups at each occurrence are optionally substituted with alkoxy, aryl, or halo; said aryl groups at each occurrence are optionally substituted with alkyl, alkoxy, or halo; and at least one atom in the compound is replaced with a radiolabeled atom; (b) allowing the compound to associate with the amyloid fibrils to provide a labeled deposit; and (c) detecting the amount and location of the labeled deposit. 9. The method of claim 8 comprising the steps of detecting the labeled deposit by gamma imaging, magnetic resonance imaging, or magnetic resonance spectroscopy. 10. The method of claim 8 comprising the step of (d) evaluating or assessing the data obtained in step (c) in an individual and optionally comparing the data with analogous data obtained from a normal human or mammal to identify, assess, or diagnose the medical condition of the individual. 11. The method of claim 10 comprising assessing the condition of an individual undergoing treatment for a condition characterized by the aggregation of amyloid fibrils. 12. The method of claim 11 wherein the condition is selected from the group consisting of Alzheimer's disease, Down syndrome, Type 2 diabetes mellitus, hereditary cerebral hemorrhage amyloidosis, amyloid A, secondary amyloidosis, familial Mediterranean fever, familial amyloid nephropathy with urticaria and deafness, amyloid lambda L-chain or amyloid kappa L-chain, A beta 2M, ATTR, familial amyloid cardiomyopathy, isolated cardiac amyloid, AIAPP or amylin insulinoa, atrial naturetic factor, procalcitonin, gelsolin, crytatin C, AApo-A-I, AApo-A-II, fibrinogen-associated amyloid; and Asor or Pr P-27 or in cases of persons who are homozygous for the apolipoprotein E4 allele, and the condition associated with homozygosity for the apolipoprotein E4 allele; and the treatment comprises administering an active agent selected from the group consisting of doxorubicin, galantamine, tacrine, selegiline, physostigmine, revistigmin, donepizil, metrifonate, milameline, xanomeline, saeluzole, acetyl L carnitine, idebenone, ENA 713, memric, quetiapine neurestrol and neuromidal. 13. A method for detecting a condition in an individual characterized by aggregation of amyloid fibrils comprising the steps of: (a) administering a compound of the following formula to a mammal or contacting said compound with a fluid or tissue sample taken from the mammal, the compound having the following formula: or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein: R1,R2,R3,R4,and R5are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; and R6is a benzopyridinyl group optionally substituted with one to three substituents selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; wherein said alkyl groups at each occurrence are optionally substituted with alkoxy, aryl, or halo; and said aryl groups at each occurrence are optionally substituted with alkyl, alkoxy, or halo; at least one atom of the compound of formula (I) being replaced with a radiolabeled atom; (b) allowing the compound to associate with the amyloid fibrils to provide a labeled deposit; and (c) detecting the condition by detecting the amount and location of the labeled deposit. 14. The method of claim 13 wherein the compound of formula (I) is incorporated in a pharmaceutically acceptable carrier. 15. The me thod of claim 13 wherein the condition is selected from the group consisting of Alzheimer's disease, Down syndrome, Type 2 diabetes mellitus, hereditary cerebral hemorrhage amyloidosis, amyloid A, secondary amyloidosis, familial mediterranean fever, familial amyloid nephropathy with urticaria and deafness, amyloid lambda L-chain or amyloid kappa L-chain, A beta 2M, ATTR, familial amyloid cardiomyopathy, isolated cardiac amyloid, AIAPP or amylin insulinoa, atrial naturetic factor, procalcitonin, gelsolin, crytatin C, AApo-A-I, AApo-A-II, fibrinogen-associated amyloid; and Asor or Pr P-27 or in cases of persons who are homozygous for the apolipoprotein E4 allele, and the condition associated with homozygosity for the apolipoprotein E4 allele. 16. The method of claim 13 wherein the condition is selected from the group consisting of Dutch hereditary cerebral hemorrhage amyloidosis amyloid A, Muckle-wells syndrome, idiopathic-associated amyloid lambda L-chain, myeloma-associated amyloid lambda L-chain, macroglobulinemia-associated amyloid lambda L-chain, idiopathic-associated amyloid kappa L-chain, myeloma-associated amyloid kappa L-chain, macroglobulinemia-associated amyloid kappa L-chain, Portuguese familial amyloid polyneuropathy, Japanese familial amyloid polyneuropathy, Swedish familial amyloid polyneuropathy, Danish familial amyloid cardiomyopathy, systemic senile amyloidosises, isolated atrial amyloid, medullary carcinoma of the thyroid, Finnish familial amyloidosis, Icelandic hereditary cerebral hemorrhage with amyloidosis, scrapie, Cruetzfeld-Jacob disease, Gertsmann-Straussler-Scheinker syndrome, and bovine spongiform encephalitis. 17. A method for staining amyloid fibrils comprising the steps of: (a) providing a compound of the formula: or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein: R1,R2,R3,R4,and R5are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; and R6is a benzopyridinyl group optionally substituted with one to three substituents selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; wherein said alkyl groups at each occurrence are optionally substituted with alkoxy, aryl, or halo; said aryl groups at each occurrence are optionally substituted with alkyl, alkoxy, or halo; and one or more atoms in the compound of formula (I) is replaced with a radiolabeled atom; (b) applying the compound to a sample containing amyloid fibrils to form a labeled deposit; and (c) detecting the labeled deposit. 18. The method of claim 17 wherein the compound is incorporated in a pharmaceutically acceptable carrier. 19. A method for detecting amyloid deposits in biopsy or postmortem human or animal tissue comprising the steps of: (a) incubating formalin-fixed biopsy or postmortem human or animal tissue with a solution of a compound of the formula: or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein: R1,R2,R3,R4,and R5are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; and R6is a benzopyridinyl group optionally substituted with one to three substituents selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, triflouromethyl, trifluoromethylether, halo, and a group of the formula --OR7,wherein R7is alkyl or aryl; wherein said alkyl groups at each occurrence are optionally substituted with alkoxy, aryl, or halo; said aryl groups at each occurrence are optionally substituted with alkyl, alkoxy, or halo; and one or more atoms in the compound of formula (I) is replaced with a radiolabeled atom; to provide a labeled deposit; and (b) detecting the labeled deposit.